Business Description
![ALX Oncology Holdings Inc ALX Oncology Holdings Inc logo](https://static.gurufocus.com/logos/0C0000BV8M.png?14)
ALX Oncology Holdings Inc
NAICS : 541714
SIC : 2834
ISIN : US00166B1052
Share Class Description:
ALXO: Ordinary SharesDescription
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 16.04 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -16.2 | |||||
3-Year EPS without NRI Growth Rate | -11 | |||||
3-Year FCF Growth Rate | -13.9 | |||||
3-Year Book Growth Rate | -29.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | 10.03 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26.52 | |||||
9-Day RSI | 23.25 | |||||
14-Day RSI | 25.17 | |||||
6-1 Month Momentum % | -58.04 | |||||
12-1 Month Momentum % | 34.07 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.39 | |||||
Quick Ratio | 4.39 | |||||
Cash Ratio | 4.08 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.8 | |||||
Shareholder Yield % | -25.07 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -95.81 | |||||
ROA % | -75.47 | |||||
ROIC % | -406.84 | |||||
ROC (Joel Greenblatt) % | -1675.55 | |||||
ROCE % | -86.94 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.79 | |||||
Price-to-Tangible-Book | 0.79 | |||||
EV-to-EBIT | 0.12 | |||||
EV-to-Forward-EBIT | -0.01 | |||||
EV-to-EBITDA | 0.12 | |||||
EV-to-Forward-EBITDA | -0.01 | |||||
EV-to-Forward-Revenue | 119.19 | |||||
EV-to-FCF | 0.16 | |||||
Price-to-Net-Current-Asset-Value | 1.11 | |||||
Price-to-Net-Cash | 1.24 | |||||
Earnings Yield (Greenblatt) % | 833.33 | |||||
FCF Yield % | -106.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALXO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ALX Oncology Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -3.63 | ||
Beta | 0.19 | ||
Volatility % | 142.17 | ||
14-Day RSI | 25.17 | ||
14-Day ATR ($) | 0.405541 | ||
20-Day SMA ($) | 3.014 | ||
12-1 Month Momentum % | 34.07 | ||
52-Week Range ($) | 2.3 - 17.825 | ||
Shares Outstanding (Mil) | 52.67 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ALX Oncology Holdings Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ALX Oncology Holdings Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
ALX Oncology Holdings Inc Frequently Asked Questions
What is ALX Oncology Holdings Inc(ALXO)'s stock price today?
The current price of ALXO is $2.39. The 52 week high of ALXO is $17.83 and 52 week low is $2.30.
When is next earnings date of ALX Oncology Holdings Inc(ALXO)?
The next earnings date of ALX Oncology Holdings Inc(ALXO) is 2024-11-13 Est..
Does ALX Oncology Holdings Inc(ALXO) pay dividends? If so, how much?
ALX Oncology Holdings Inc(ALXO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |